{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:23:05Z","timestamp":1776378185862,"version":"3.51.2"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10147-025-02847-6","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T17:45:44Z","timestamp":1754070344000},"page":"2003-2011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study"],"prefix":"10.1007","volume":"30","author":[{"given":"Hisateru","family":"Yasui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotoshi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Amagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Choda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taito","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Shiratori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonal","family":"Bordia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2847_CR1","unstructured":"Ferlay J, Ervik M, Lam F et al (2024) Global cancer observatory: cancer today (version 1.1). International Agency for Research on Cancer. https:\/\/gco.iarc.who.int\/today. Accessed 05\/28\/2024 2024"},{"key":"2847_CR2","unstructured":"Foundation for Promotion of Cancer Research (2024) Cancer statistics in Japan 2024. Foundation for Promotion of Cancer Research. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/2024_en.html. Accessed 05\/8\/2024 2024"},{"issue":"3","key":"2847_CR3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang YJ, Feng-Yi F et al (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18(3):476\u2013484 https:\/\/doi.org\/10.1007\/s10120-014-0402-y","journal-title":"Gastric Cancer"},{"issue":"1","key":"2847_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdy498","volume":"30","author":"K Muro","year":"2019","unstructured":"Muro K, Lordick F, Tsushima T et al (2019) Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol 30(1):34\u201343 https:\/\/doi.org\/10.1093\/annonc\/mdy498","journal-title":"Ann Oncol"},{"key":"2847_CR5","doi-asserted-by":"publisher","unstructured":"Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) (2023) Gastric Cancer 26(1):1\u201325. https:\/\/doi.org\/10.1007\/s10120-022-01331-8","DOI":"10.1007\/s10120-022-01331-8"},{"key":"2847_CR6","doi-asserted-by":"publisher","unstructured":"Wang FH, Zhang XT, Li YF et al (2021) The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond) 41(8):747\u2013795. https:\/\/doi.org\/10.1002\/cac2.12193","DOI":"10.1002\/cac2.12193"},{"issue":"10294","key":"2847_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27\u201340 https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2","journal-title":"Lancet"},{"issue":"2","key":"2847_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(2):234\u2013247 https:\/\/doi.org\/10.1016\/s1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"issue":"8","key":"2847_CR9","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1111\/cas.15462","volume":"113","author":"K Yamaguchi","year":"2022","unstructured":"Yamaguchi K, Minashi K, Sakai D et al (2022) Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer. Cancer Sci 113(8):2814\u20132827 https:\/\/doi.org\/10.1111\/cas.15462","journal-title":"Cancer Sci"},{"issue":"11","key":"2847_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh D-Y, Ya\u00f1ez P et al (2023) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 24(11):1181\u20131195 https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6","journal-title":"Lancet Oncol"},{"key":"2847_CR11","doi-asserted-by":"publisher","unstructured":"Miettinen O, Nurminen M (1985) Comparative analysis of two rates. Stat Med 4(2):213\u2013226. https:\/\/doi.org\/10.1002\/sim.4780040211","DOI":"10.1002\/sim.4780040211"},{"issue":"Series b part 1","key":"2847_CR12","first-page":"134","volume":"62","author":"KY Liang","year":"2017","unstructured":"Liang KY, Zeger SL (2017) Longitudinal data analysis of continuous and discrete responses for pre-post designs. Indian J Stat 62(Series b part 1):134","journal-title":"Indian J Stat"},{"issue":"4","key":"2847_CR13","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1007\/s12325-024-03069-4","volume":"42","author":"S Qin","year":"2025","unstructured":"Qin S, Bai Y, Li J et al (2025) First-line pembrolizumab plus chemotherapy for HER2-negative advanced gastric cancer: China subgroup analysis of the randomized phase 3 KEYNOTE-859 study. Adv Ther 42(4):1892\u20131906 https:\/\/doi.org\/10.1007\/s12325-024-03069-4","journal-title":"Adv Ther"},{"issue":"4_suppl","key":"2847_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1200\/JCO.2025.43.4_suppl.428","volume":"43","author":"SY Rha","year":"2025","unstructured":"Rha SY, Lee J, Ryu M-H et al (2025) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859. J Clin Oncol 43(4_suppl):428\u2013428 https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.428","journal-title":"J Clin Oncol"},{"key":"2847_CR15","doi-asserted-by":"publisher","unstructured":"Kubota Y, Aoki Y, Kawazoe A et al (2022) Role of nivolumab in the management of first-line unresectable advanced or recurrent gastric cancer in combination with chemotherapy: lessons from the Japanese experience. Cancer Manag Res 14:3083\u20133094. https:\/\/doi.org\/10.2147\/cmar.S351791","DOI":"10.2147\/cmar.S351791"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02847-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02847-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02847-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:38:17Z","timestamp":1758872297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02847-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2847"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02847-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hisateru Yasui reports honoraria from Chugai Pharma, MSD, and Yakult Honsha and research funding (to the institution) from MSD. Masaki Aizawa reports honoraria from Bristol Myers Squibb KK, MSD, Ono Pharmaceutical, Medtronic, Taiho Pharmaceutical, and Johnson & Johnson\/MedTech. Kensei Yamaguchi reports honoraria from Bristol Myers Squibb KK, Eli Lilly Japan KK, Taiho Pharmaceutical Co., Ltd., and Ono. Akihito Kawazoe reports honoraria from Ono Pharmaceutical, Taiho, Bristol Myers Squibb, Daiichi Sankyo\/UCB Japan, and Eli Lilly and research funding from AstraZeneca (institution) and AbbVie. Hiroki Hara reports honoraria from Astellas, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, Merck Biopharma, Miyarisan Pharmaceutical, MSD, Ono Pharmaceutical, Taiho, Takeda, and Yakult and research funding from ALX Oncology, Amgen, Astellas, AstraZeneca, Bayer, Chugai, Daiichi Sankyo, Janssen, Jazz Pharma, MSD, Ono Pharmaceutical and Taiho. Masahiro Tsuda reports research funding from Toray. Hirokazu Shoji reports honoraria from Ono Pharmaceutical and Bristol Myers Squibb, and research grants from Ono Pharmaceutical and Takeda Pharmaceuticals. Naotoshi Sugimoto reports grants from MSD, Ono Pharmaceutical, Taiho Pharmaceutical, Lilly Japan, Daiichi Sankyo, Sumitomo Pharma, Chugai Pharma, BeiGene, Solasia Pharma, Astellas Pharma, and Eisai. Nobuhiro Shibata reports consulting fees for advisory board membership from Kyowa Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd.; honoraria from Kyowa Kirin Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Merck Biopharma Co., Ltd., and Bristol Myers Squibb K.K.; and research funding from Daiichi Sankyo Co., Ltd., MSD K.K., AstraZeneca K.K., and Eli Lilly Japan KK. Kenji Amagai reports research funding from MSD. Taito Esaki reports research funding from MSD, Ono Pharmaceutical, Chugai, Amgen, ALX Oncology, Seagen, Taiho, Daiichi Sankyo, Pfizer, Jazz Pharmaceuticals, Asahi Kasei Pharma, Quintiles, Astellas Amgen Biopharma, Novartis, and Syneos Health. Shigenori Kadowaki reports honoraria from Ono Pharmaceutical, Taiho, MSD, Daiichi Sankyo, Merck KGaA, Bristol Myers Squibb, Eli Lilly, Chugai, Bayer, Eisai, and Novartis and research funding from Ono Pharmaceutical, Taiho, MSD, Nobel, Janssen, Bayer, Eli Lilly, Chugai, Daiichi Sankyo, AbbVie, and AstraZeneca. Shinichi Shiratori is an employee of MSD KK, Tokyo, Japan, and owns stock in Merck & Co., Inc., Rahway, NJ, USA. Shirong Han is an employee of MSD KK, Tokyo, Japan, and may hold stock in Merck & Co., Inc., Rahway, NJ, USA. Sonal Bordia is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and owns stock in Merck & Co., Inc., Rahway, NJ, USA. Kohei Shitara reports receiving personal fees for consulting and advisory roles from Bristol Myers Squibb, Takeda, Ono Pharmaceutical, Novartis, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Merck, Astellas, Guardant Health Japan, Janssen, AstraZeneca, Zymeworks Biopharmaceuticals, ALX Oncology Inc., Bayer, GlaxoSmithKline KK, HEALIOS KK, Moderna, Inc., and Arcus Biosciences, Inc.; honoraria from Bristol Myers Squibb, Ono Pharmaceutical, Janssen, Eli Lilly, Astellas, and AstraZeneca; and research funding from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck, Amgen, Eisai, PRA Health Sciences, Syneos Health, AstraZeneca, PPD-SNBL KK, and Toray Industries, Inc. Industries, Inc. Yasuhiro Choda and Shiro Iwagami declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data were described, in part, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) annual meeting held virtually January 18\u201320, 2024.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Meeting presentation"}}]}}